mad2l2 Antibody

What is MAD2L2 and what cellular functions are studied using MAD2L2 antibodies?

MAD2L2 (also known as MAD2B or REV7) is a multifunctional protein that plays crucial roles in several cellular pathways. It was initially identified as a component of the mitotic spindle assembly checkpoint that prevents anaphase onset until chromosomes are properly aligned. Research has revealed additional critical functions including:

• DNA damage response: MAD2L2 is essential for interstrand crosslink repair and functions in translesion DNA synthesis (TLS)

• Replication fork protection: Studies show MAD2L2 prevents excessive processing of stalled replication forks by MRE11

• DNA double-strand break repair: As a component of the Shieldin complex

• Cancer progression: Elevated expression has been observed in multiple cancer types including glioma, melanoma, ovarian and colon cancers

MAD2L2 is ubiquitously expressed and has a molecular weight of approximately 24 kDa. Antibodies targeting this protein enable researchers to investigate its localization patterns, expression levels, and interactions with other proteins across these diverse functional contexts.

What types of MAD2L2 antibodies are commonly used in research?

Researchers typically employ several types of MAD2L2 antibodies depending on their experimental needs:

Most commercially available MAD2L2 antibodies are developed in rabbits and target the full-length protein (amino acids 1-211) or specific regions. The choice between antibody types depends on the specific application, with monoclonals often preferred for consistent results across experiments, while polyclonals may offer greater sensitivity for detecting low-abundance targets .

What validated applications are MAD2L2 antibodies suitable for?

MAD2L2 antibodies have been validated for multiple research applications, with specific methodological considerations for each:

When designing experiments, researchers should note that MAD2L2 localizes to multiple cellular compartments including the cytoplasm, nucleus, cytoskeleton, and spindle, requiring appropriate fixation and permeabilization protocols for accurate detection .

What are the common host species and reactivity profiles for MAD2L2 antibodies?

The choice of host species for MAD2L2 antibody production impacts specificity, applications, and experimental design. Based on available information:

When selecting a MAD2L2 antibody based on host species, researchers should consider:

• The species of their experimental samples to avoid cross-reactivity

• Secondary antibody compatibility in multi-labeling experiments

• The need for species-matched blocking reagents to minimize background

The immunogen used for antibody production is typically a recombinant fusion protein containing amino acids 1-211 of human MAD2L2 (NP_006332.3), which shares high sequence homology with mouse and rat orthologs, enabling cross-species reactivity .

How can researchers validate the specificity of a MAD2L2 antibody for their experimental system?

Comprehensive validation of MAD2L2 antibody specificity is crucial for generating reliable research data. A multi-approach validation strategy should include:

• Genetic approaches:

  • siRNA/shRNA knockdown of MAD2L2: Compare antibody signal in wild-type versus knockdown cells

  • CRISPR-Cas9 knockout: Generate MAD2L2-null cells as the gold standard negative control

  • Overexpression: Transfect cells with tagged MAD2L2 constructs and confirm co-localization with antibody staining

• Biochemical validation:

  • Western blot analysis: Confirm single band at expected molecular weight (24 kDa)

  • Peptide competition assay: Pre-incubate antibody with immunizing peptide to block specific binding

  • Mass spectrometry validation: Perform immunoprecipitation followed by mass spectrometry to confirm target identity

• Control samples:

  • Include tissues/cells known to express high levels of MAD2L2 (based on research: A-375, K-562, SW480, HeLa, Mouse skeletal muscle)

  • Test in multiple cell lines with varying expression levels

  • Compare with mRNA expression data from public databases

Research has shown that MAD2L2 mutations (Y63A, W171A, and Y63A/W171A) significantly impact protein interactions, which can serve as useful controls for antibody validation experiments targeting these regions .

What experimental design principles should be applied when using MAD2L2 antibodies for co-immunoprecipitation studies?

Co-immunoprecipitation (co-IP) studies with MAD2L2 antibodies require careful experimental design to preserve physiologically relevant protein-protein interactions while minimizing artifacts. Key methodological considerations include:

• Antibody selection:

  • Choose antibodies validated specifically for immunoprecipitation

  • Consider epitope location relative to known interaction domains

  • Research indicates MAD2L2 interacts with proteins through specific regions (e.g., Y63 and W171 residues are critical for CAMP interaction); select antibodies that don't interfere with these sites

• Lysis conditions:

  • Use gentle lysis buffers that preserve protein-protein interactions

  • Optimize salt concentration (typically 100-150 mM NaCl) to maintain specific interactions

  • Include protease and phosphatase inhibitors to prevent degradation

  • Consider cell synchronization for cell-cycle dependent interactions, as MAD2L2 functions vary during mitosis

• Controls and validation:

  • Include IgG control from the same species as the MAD2L2 antibody

  • Validate with reciprocal co-IP (IP with antibody against predicted interacting protein)

  • For known interactions (e.g., MAD2L2-CAMP), use mutants (W334A/K335A, W334A/P341A) described in research as negative controls

Based on published research, MAD2L2 has been shown to interact with proteins involved in DNA repair (REV1, REV3), mitosis (CAMP), and cellular adhesion (ADAM9, ADAM15), providing potential positive controls for co-IP experiments .

How does MAD2L2 expression vary across different cancer types, and what implications does this have for antibody selection?

MAD2L2 expression exhibits significant variation across cancer types, influencing experimental design and antibody selection strategies. Based on research findings:

• Expression patterns across cancer types:

  • Glioblastoma (GBM): Significantly elevated expression compared to normal brain tissue, with expression increasing with tumor grade (II-IV)

  • Ovarian cancer: Overexpression observed, particularly in higher-grade tumors; correlates with reduced survival rates

  • Melanoma: Higher expression compared to adjacent tissues

  • Pan-cancer analysis: Generally elevated in most cancer tissues compared to normal tissues

• Prognostic significance:

  • High expression correlates with poor prognosis in multiple cancers

  • In glioblastoma, MAD2L2 expression levels can effectively distinguish between GBM and lower-grade gliomas (LGG) as demonstrated by ROC analysis

  • Univariate cox analysis demonstrated a hazard ratio greater than 1 for MAD2L2 in glioma patients

• Antibody selection implications:

  • Sensitivity requirements: For cancers with moderate expression, higher-sensitivity antibodies may be needed

  • Specificity across isoforms: Ensure antibodies detect cancer-relevant isoforms

  • Background considerations: Cancer tissues often have higher autofluorescence and non-specific binding

For quantitative studies comparing MAD2L2 across cancer types, standardized protocols and consistent antibody lots are essential to minimize technical variation.

How can researchers design experiments to study MAD2L2's role in replication fork protection using specific antibodies?

Investigating MAD2L2's role in replication fork protection requires carefully designed experiments that leverage specific antibodies. Based on research showing MAD2L2's involvement in fork protection and recovery:

• Replication fork dynamics analysis:

  • DNA fiber assay: Use CldU/IdU pulse-labeling to measure fork progression rates

  • Methodology: Label cells with CldU (30 min) followed by IdU (1 hr) with or without hydroxyurea (HU)

  • Quantify IdU tract lengths as a measure of fork progression

  • Compare MAD2L2-depleted vs. control cells

  • Antibody application: Use anti-CldU and anti-IdU antibodies for detection; anti-MAD2L2 antibodies for validating knockdown efficiency

• Replication fork restart assessment:

  • Sequential labeling scheme: CldU (red) → HU treatment → IdU (green)

  • Categorize forks as: stalled (red only), restarting (red-green), or newly fired origins (green only)

  • Research shows MAD2L2-depleted cells exhibit a severe defect in fork restart, with increased fork stalling and reduced percentage of restarting forks

• Replication fork protection analysis:

  • Nascent DNA protection assay: Label cells with BrdU, induce fork stalling, and measure ssDNA formation

  • Antibody requirements: Highly specific MAD2L2 antibodies validated for IP applications

• MRE11 nuclease activity assessment:

  • Research indicates MAD2L2 prevents excessive processing of stalled replication forks by MRE11

  • Co-IP experiments: MAD2L2 antibodies to pull down complexes and probe for MRE11

Research has documented that MAD2L2 depletion leads to increased chromosomal aberrations after hydroxyurea treatment, providing a methodological foundation for these studies .

What are the implications of MAD2L2 localization patterns for immunofluorescence experimental design?

MAD2L2's complex localization patterns have significant implications for immunofluorescence (IF) experimental design. Based on research showing MAD2L2 localization in multiple cellular compartments:

• Subcellular localization profiles:

  • Research indicates MAD2L2 localizes to: cytoplasm, nucleus, cytoskeleton, spindle, and mitotic chromosomes

  • Dynamic relocalization: MAD2L2 shows different localization patterns during mitosis versus interphase

  • Context-dependent patterns: Mutations (Y63A, W171A) affect localization to mitotic chromosomes

• Co-localization studies:

  • Mitotic spindle markers: α-tubulin, γ-tubulin for centrosome examination

  • Nuclear markers: DAPI for DNA, specific markers for sub-nuclear structures

  • DNA damage markers: γH2AX, 53BP1 to assess localization to damage sites

  • Cell cycle markers: Phospho-histone H3 to identify mitotic cells

• Cell cycle considerations:

  • Research shows wild-type MAD2L2 is co-localized with full-length CAMP in the mitotic spindle and mitotic chromosomes

  • Time-course experiments: Capture dynamic localization changes during cell cycle progression

• Controls and validation:

  • Knockdown controls: siRNA/shRNA against MAD2L2 to confirm antibody specificity

  • Competing peptide: Pre-incubation with immunizing peptide should abolish specific signal

  • Biological controls: Include known localization patterns during specific cellular states

Research highlights that MAD2L2 mutations (Y63A, W171A) affect its localization to mitotic chromosomes while wild-type MAD2L2 co-localizes with CAMP in the mitotic spindle and chromosomes, demonstrating the importance of these considerations for experimental design .

How can researchers troubleshoot conflicting data between different MAD2L2 antibodies?

Resolving conflicting data between different MAD2L2 antibodies requires systematic troubleshooting and validation approaches:

• Antibody characterization:

  • Epitope mapping: Determine the exact binding sites of each antibody

  • Compare monoclonal versus polyclonal antibodies: Discrepancies could reflect epitope-specific differences

  • Species cross-reactivity: Verify if differences relate to species-specific detection

  • Lot-to-lot variability: Test multiple lots of the same antibody for consistency

• Validation with genetic controls:

  • siRNA/shRNA knockdown: All true signals should diminish with target reduction

  • CRISPR/Cas9 knockout: The gold standard negative control

  • Overexpression: Tagged MAD2L2 constructs should show corresponding signal increases

  • Epitope mutations: Introduce mutations in the epitope region to confirm specificity

• Technical optimization:

  • Sample preparation: Test multiple lysis conditions (RIPA, NP-40, etc.)

  • Blocking conditions: Optimize blocking agents to reduce non-specific binding

  • Antibody concentration: Perform titration series to identify optimal working dilutions

  • Incubation conditions: Test different durations and temperatures

• Data integration strategies:

  • Weighted analysis: Give preference to results from better-validated antibodies

  • Triangulation: Look for consensus across multiple antibodies and techniques

  • Consider context: Some antibodies may perform better in specific applications

Structural studies of MAD2L2 have identified critical regions for protein-protein interactions, which may help explain discrepancies in antibody recognition when MAD2L2 is bound to various partners .

What techniques can improve signal-to-noise ratio when using MAD2L2 antibodies in immunohistochemistry?

Optimizing signal-to-noise ratio for MAD2L2 immunohistochemistry (IHC) requires systematic technical refinements:

• Antigen retrieval optimization:

  • Compare heat-induced (citrate buffer, pH 6.0) versus enzymatic retrieval methods

  • Optimize retrieval duration and temperature

  • Test pressure-cooking versus microwave methods

  • For formalin-fixed tissues, extend retrieval times to overcome extensive cross-linking

• Blocking strategies:

  • Use species-matched serum corresponding to secondary antibody

  • Employ dual blocking with both serum and BSA

  • Consider specialized blocking agents for endogenous peroxidase/phosphatase

  • For tissues with high background, include additional blocking steps with 5-10% milk proteins

• Antibody optimization:

  • Titrate primary antibody concentration (recommended dilutions for IHC are typically 1:50 - 1:200)

  • Extend primary antibody incubation (overnight at 4°C versus 1-2 hours at room temperature)

  • Test different antibody diluents containing stabilizers and background reducers

  • For monoclonal antibodies, compare different clones targeting different epitopes

• Detection system refinements:

  • Compare polymer-based versus ABC detection systems

  • Use tyramide signal amplification for low-abundance targets

  • Test chromogens with different sensitivities (DAB, AEC, etc.)

  • For fluorescent detection, employ direct-labeled primaries to reduce background

Based on research, MAD2L2 is expressed in multiple cellular compartments including cytoplasm and nucleus, making clear discrimination between specific signal and background particularly important for accurate localization studies .

How should researchers approach MAD2L2 studies in cancer models using antibody-based methods?

MAD2L2's role in cancer progression requires specialized approaches when using antibody-based detection methods:

• Model selection considerations:

  • Cell line selection: Research shows differential MAD2L2 expression across cancer types

  • Glioblastoma (GBM): MAD2L2 promotes stemness and malignant behaviors through c-MYC regulation

  • Ovarian cancer: MAD2L2 enhances cell proliferation and migration; inhibits ferroptosis while increasing mTOR signaling

  • Include appropriate non-cancerous controls for each tissue type

• Experimental design principles:

  • Knockdown/overexpression validation: Western blotting with MAD2L2 antibodies confirms modulation

  • Proliferation assays: Research shows knockdown/overexpression of MAD2L2 inhibits/promotes cancer cell proliferation

  • Migration and invasion assays: MAD2L2 affects these key cancer hallmarks

  • Stemness assessment: MAD2L2 maintains glioblastoma stemness

• Antibody validation in cancer context:

  • Confirm antibody recognition in cancer-relevant conditions

  • Validate in multiple cancer cell lines from the same tissue origin

  • Compare antibody detection with mRNA expression levels

  • Test antibody performance in patient-derived samples

• Mechanistic studies:

  • Research indicates MAD2L2 is regulated by E2F-1 in glioma, which could be explored using ChIP assays with MAD2L2 antibodies

  • MAD2L2's relationship with key oncogenic signaling pathways (e.g., mTOR) can be examined using co-IP and Western blotting

  • DNA repair function analysis using DNA damage markers requires specific antibody combinations

Recent studies have demonstrated that MAD2L2 contributes to tumor progression through multiple mechanisms, making it an important target for cancer research requiring well-validated antibody-based approaches .

How can MAD2L2 antibodies be employed to investigate its role in DNA repair pathways?

MAD2L2's involvement in multiple DNA repair pathways presents unique opportunities for antibody-based investigations:

• Interstrand crosslink (ICL) repair:

  • Research shows MAD2L2 is essential for ICL repair, with MAD2L2 depletion sensitizing cells to crosslinking agents cisplatin and mitomycin C

  • Methodological approach: Combine MAD2L2 antibody detection with ICL-specific markers

  • Quantify MAD2L2 recruitment to damage sites using IF after crosslinker treatment

  • Examine protein complex formation using co-IP with MAD2L2 antibodies

• Translesion DNA synthesis (TLS):

  • MAD2L2 functions in TLS as REV7, interacting with REV1 and REV3

  • Experimental design: Use MAD2L2 antibodies in combination with other TLS factor antibodies

  • Assess co-localization at replication-blocking lesions

  • Examine temporal dynamics of complex formation

• Double-strand break repair:

  • MAD2L2 is a component of the Shieldin complex in DNA double-strand break repair

  • Methodology: Use MAD2L2 antibodies for ChIP assays at DSB sites

  • Quantify MAD2L2 recruitment kinetics using time-course IF studies

  • Analyze pathway choice (NHEJ vs. HR) through co-IP studies with pathway-specific factors

• Replication stress response:

  • Research demonstrates MAD2L2 contributes to replication fork protection and recovery

  • Global DNA synthesis in MAD2L2-depleted cells can be measured by pulse-labeling S-phase cells with EdU

  • MAD2L2 antibodies can validate knockdown efficiency in these studies

Recent findings that MAD2L2 depletion causes chromosomal aberrations after replication stress provides a foundation for investigating its genome maintenance functions using antibody-based approaches .

What consideration should be given to MAD2L2 structural features when selecting antibodies for interaction studies?

When investigating MAD2L2's protein-protein interactions, epitope selection is critical as it can directly impact the detection of biologically relevant complexes:

• Critical interaction domains:

  • Research has identified residues Y63 and W171 as crucial for MAD2L2 interaction with CAMP

  • The W334/K335/P341 region of CAMP is essential for binding to MAD2L2

  • MAD2L2 interacts with REV1, REV3, ADAM9, and ADAM15 proteins through specific domains

• Functional domains to consider:

  • DNA binding regions: Important for chromatin association and DNA repair functions

  • Mitotic spindle association domains: Critical for cell cycle checkpoint functions

  • Protein-protein interaction interfaces: May be masked when MAD2L2 is in complex with partners

• Recommendations for antibody selection:

  • For detecting total MAD2L2 regardless of interaction state: Select antibodies targeting conserved epitopes away from known interaction surfaces

  • For studying specific interactions: Consider using antibodies that don't compete with the interaction of interest

  • For disrupting specific interactions: Antibodies targeting key interaction residues may be useful as blocking reagents

Research describes MAD2L2 interactions with specific proteins through defined regions. For example, the interaction with CAMP involves a specific binding region (containing WK-4, residues 325-344) that was crystallographically defined . Antibodies targeting this interface might interfere with the interaction, while antibodies targeting other regions would allow detection of the complex.